Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$4.34 - $6.58 $0 - $0
0 New
0 $0
Q2 2024

Jul 23, 2024

BUY
$4.19 - $6.23 $0 - $0
0 New
0 $0
Q1 2024

Apr 30, 2024

BUY
$5.69 - $8.08 $0 - $0
0 New
0 $0
Q4 2023

Feb 07, 2024

BUY
$3.77 - $8.39 $0 - $0
0 New
0 $0
Q3 2023

Oct 30, 2023

BUY
$5.2 - $8.77 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023

BUY
$5.2 - $8.77 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023

BUY
$5.86 - $7.93 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023

BUY
$5.85 - $9.84 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023

BUY
$6.88 - $9.55 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022

BUY
$8.19 - $13.2 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022

BUY
$7.65 - $14.24 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022

BUY
$13.02 - $20.78 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022

BUY
$19.35 - $25.54 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021

BUY
$21.65 - $39.49 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021

BUY
$15.5 - $22.48 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021

BUY
$14.84 - $22.23 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021

BUY
$9.4 - $16.7 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020

BUY
$10.54 - $24.96 $0 - $0
0 New
0 $0
Q2 2020

Aug 13, 2020

BUY
$21.87 - $33.11 $0 - $0
0 New
0 $0
Q1 2020

May 13, 2020

BUY
$16.25 - $35.28 $0 - $0
0 New
0 $0
Q4 2019

Feb 14, 2020

BUY
$14.17 - $20.3 $0 - $0
0 New
0 $0
Q3 2019

Nov 13, 2019

BUY
$14.42 - $22.2 $0 - $0
0 New
0 $0
Q2 2019

Aug 13, 2019

BUY
$16.26 - $26.42 $0 - $0
0 New
0 $0
Q1 2019

May 15, 2019

BUY
$15.97 - $22.5 $0 - $0
0 New
0 $0

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $159M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.